A new-fangled drug, Saphris, manufactured by the Schering-Plough drug company, has received the approval of the FDA for treatment of adult schizophrenia and bipolar disorder I. Mental infirmity such as schizophrenia and bipolar I disorder exert tremendous toll on the lives of those inflicted and their kin as it necessitates long endearing treatments and rehabilitation. Thomas Laughren, director of the section of psychiatry produce, Center for Drug Evaluation and Research, FDA stated in a news broadcast that effectual medication could assist individuals with mental debility to avail greater independence in their daily lives. The FDA has pointed out the general indicators of schizophrenia that comprise of inapt disbelief or being overly suspicious, hallucinating, irrational convictions such as thinking that people around them are constantly contriving and overpowering their thought process. Bipolar I disorder is an unremitting, vicious, intermittent psychiatric disorder that leads  [...]